Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Electrolux Professional AB (publ) listed for trading at Nasdaq Stockholm

Electrolux Professional AB (publ) (”Electrolux Professional”) was listed on Nasdaq Stockholm today and the company’s shares of series A and series B have commenced trading. The listing of Electrolux Professional is a result of the Extraordinary General Meeting of AB Electrolux decision on February 21, 2020 to distribute all shares in Electrolux Professional to the shareholders of AB Electrolux.  “I am very pleased that Electrolux Professional’s listing date has arrived. Although we are experiencing challenging times with the global impact of the coronavirus, it is with a lot of

Solteq Plc cancels the Annual General Meeting on 1 April 2020 and postpones it to a later date

Solteq Plc, Stock Exchange Bulletin, 23 March 2020 at 10:30 am   Due to the Coronavirus (COVID-19) epidemic in Finland, the Board of Directors of Solteq Plc has decided to cancel the Annual General Meeting scheduled for 1 April 2020. The company shall convene a new meeting at a date to be confirmed later. Solteq Plc takes the Coronavirus situation seriously and does not want to jeopardise the health of employees, shareholders and other stakeholders attending the Annual General Meeting. The Annual General Meeting shall be held when the Coronavirus situation allows it. A new

Lehto Group Plc will start to repurchase the company’s own shares

Lehto Group PlcStock exchange release23 March 2020 at 10.15 a.m.Lehto Group Plc’s (”Lehto” or the “Company”) Board of Directors has on 20 March 2020 decided on the basis of the authorisation granted by the Annual General Meeting of shareholders held on 29 March 2019 to commence repurchasing the Company’s own shares. The shares shall be repurchased to meet the Company's obligations under the share-based incentive plans or for other purposes defined in the authorization of the Annual General Meeting. The share repurchases shall start on 23 March 2020, at the earliest, and end by 31 May

Steps forward in corporate responsibility taken by Gasum in 2019

The energy company Gasum promotes sustainable development in line with its strategy. Gasum has published its key corporate responsibility achievements in 2019. The company improved its customers’ access to cleaner energy in road and maritime transport, industry and energy production. Gasum’s safety and security culture underwent strong development, which resulted in many steps forward.Gasum is taking determined steps to promote sustainable development in accordance with the principles of circular economy and by providing cleaner energy solutions in the Nordic countries. The company’s

Nomination Committee proposes Torben Jørgensen for new chairman of Genovis

Genovis’ Nomination Committee proposes new election of Torben Jørgensen to serve on the Board of Directors and as Chairman of the Board at the Annual General Meeting on May 5.Torben Jørgensen was born in 1952 and is currently Chairman of the Board of Biotage AB and Atlas Antibodies AB. He also serves on the boards of Micropos AB and Intervacc AB. Previous appointments include CEO and President of Biotage AB from 2006 to 2020, Affibody AB from 2001 to 2005, Karo Bio from 2000 to 2001 and DAKO AB from 1988 to 1999.   “The Nomination Committee is pleased to be able to propose Torben

Wallenberg Clinical Scholars: SEK 60 million in funding for research physicians

This year’s Wallenberg Clinical Scholars, from Lund, Linköping and Stockholm, are aiming to find methods that slow the progression of Huntington’s disease, contribute to the development of more effective pain medication, refine the treatment of overweight, and cure rheumatoid arthritis. This is clinical research that can be of direct benefit in the healthcare system.Wallenberg Clinical Scholars each receive funding worth SEK 15 million over a five-year period, with the opportunity to extend this for an additional five years.    “The Foundation primarily supports basic research, but we

Wallenberg Clinical Scholars: SEK 60 million in funding for research physicians

This year’s Wallenberg Clinical Scholars, from Lund, Linköping and Stockholm, are aiming to find methods that slow the progression of Huntington’s disease, contribute to the development of more effective pain medication, refine the treatment of overweight, and cure rheumatoid arthritis. This is clinical research that can be of direct benefit in the healthcare system.Wallenberg Clinical Scholars each receive funding worth SEK 15 million over a five-year period, with the opportunity to extend this for an additional five years. “The Foundation primarily supports basic research, but we also

Lindab International AB (publ): Notice to attend Lindab's Annual General Meeting on April 29, 2020

The shareholders of Lindab International AB (publ) (the “Company” or “Lindab”) are hereby invited to attend the Annual General Meeting to be held at 3 pm (CEST) on Wednesday April 29, 2020 at Hotel Skansen, Båstad. Registration for the Annual General Meeting begins at 2.30 pm (CEST).Corona virus information (covid-19)Due to the recent development of the spread of the corona virus (covid-19), certain precautions have been taken for the Annual General Meeting. Measures are being extended to reduce the risk of infection spreading. · Shareholders should consider using the opportunity to

Ultra running solicitor starts her ideal job with leading legal firm in dream location

Ultra running solicitor Krystal Garnett couldn’t be in a better place today when it comes to starting her new job.   Krystal has landed her ideal role at top legal firm Cartmell Shepherd Solicitors in a part of the country she loves.   “I am so excited to get started. Cartmell Shepherd has such a good reputation, they are held in such high regard, I know they are one of the best firms to work for.   “They are clearly known for their expertise and their strength in depth across the team, with them being a larger firm. But they are also known for being a friendly team.

Amended dividend proposal for 2019

Due to the uncertainty caused by COVID-19, the Board of Directors of JM is proposing to amend the dividend for 2019. The Board of Directors of JM AB will propose to the general meeting on March 26 a dividend of SEK 6.25, while also maintaining its ambition of a total dividend of SEK 12.50 in 2020.Assuming that the global situation has stabilized and the visibility for the housing market has reasonably improved, the ambition is to convene an extraordinary general meeting later in 2020 to propose resolution on an additional dividend.JM’s business development has been stable so far in the

2cureX provides update regarding the COVID-19 impact on ongoing clinical programs

Copenhagen — March 23, 2020 — 2cureX AB (“2cureX”, NASDAQ: 2CUREX) announced today that the corona-crisis will not delay 2cureX’s intervention study where the IndiTreat test is guiding treatment of patients with metastatic colorectal cancer (ClinicalTrials.gov Identifier: NCT03251612). Patient recruitment will continue as planned and finalization of the trial is expected as previously communicated in Q3 of 2020.Vejle University Hospital has informed 2cureX that patient recruitment for the metastatic colorectal cancer trial will be upheld. The project is in its late stage and patient

Inhalation Sciences ships second fully commercialized DissolvIt module in one week

Following the historic shipment of its first commercialized DissolvIt[®] in vitro module, Inhalation Sciences has shipped a second module, to a returning pharmaceutical customer, within the same week. The customer placed the original purchase order for DissolvIt, worth 75,000 Euro (835,000 SEK), in December 2018. “We’ve long known DissolvIt was in demand” says CEO Manoush Masarrat, “this really proves it.”The latest, second commercialized module has been shipped to a long-term ISAB pharma company in Southern Europe. After ten years in development DissolvIt has been tested in many contract

Aker BP updates its investment program

Aker BP is updating its investment program and financial framework in order to secure additional financial optionality in response to the high uncertainty caused by the COVID-19 crisis.   The main changes to Aker BP’s investment program are: · Non-sanctioned field development projects are put on hold. For 2020, this represents a capex reduction of 20 percent compared to previous guidance. For 2021-22 the initial estimate is a reduction in capital spend of USD 1-2 billion · Exploration spending is reduced by 20 percent in 2020, with further significant reductions planned for 2021-

Alfa Laval wins SEK 60 million renewable energy order in Sweden

Alfa Laval – a world leader in heat transfer, centrifugal separation and fluid handling – has won an order from the energy company St1 for a process line to be installed in a new biorefinery in Sweden. The order has a value of approximately SEK 60 million and is booked in the Food Systems unit of the Food & Water Division. Deliveries are scheduled for 2021.The order includes various pieces of equipment for the new St1 biorefinery plant to be built in Gothenburg, Sweden. The equipment will remove various impurities from waste fats and oils, which later will be converted into renewable fuels.

Lindab’s Board of Directors changes dividend proposal – last year's dividend level is maintained

The Board of Directors proposes to the AGM to decide on a cash dividend of SEK 1.75 per share (1.75), which differs from SEK 3.60 per share previously communicated. The Board of Directors’ decision has been made in light of the general uncertainty created by the measures taken to slow down the spread of covid-19.Lindab increased its profits in 2019 and has a strong financial position. The previous dividend proposal reflected Lindab's solid balance sheet and strong results and the updated dividend policy from December 2019. At present, the global financial outlook is very uncertain. The

BlackRock's indirect shareholding in UPM has gone below the threshold of 5 per cent

UPM-Kymmene Corporation       Stock Exchange Release (Flagging Release)      23 March 2020 at 09:30 EET BlackRock's indirect shareholding in UPM has gone below the threshold of 5 per cent UPM-Kymmene Corporation has on 20 March 2020 received an announcement under Chapter 9, Section 5 of the Securities Markets Act, according to which BlackRock, Inc.'s indirect shareholding of UPM shares and voting rights has gone below the threshold of 5 per cent on 19 March 2020. According to the announcement, BlackRock, Inc.’s indirect shareholding in UPM has decreased to 26,393,826 shares,

Interim Report 1 September 2019 - 29 February 2020

SECOND QUARTER, DECEMBER 1, 2019 - FEBRUARY 29, 2020 IN SUMMARY · Net sales decreased to SEK 561 M (604). · Comparable sales for the Group on all national markets decreased by -11.6 percent. · Sales for comparable units in Sweden decreased by -9.4 percent, compared to the market upturn of 0.1 percent. · Operating income was SEK -52 M (-28). · Operating income, excluding IFRS 16, the new accounting standard, amounted to SEK -55 M (-28). · Profit after tax amounted to SEK -63 M (-35). · Earnings per share was SEK -0.66 (-1.02).   · Cash flow from operating activities

RNB has today applied for Company Reorganisation for the subsidiaries Brothers, Departments & Stores and Polarn O. Pyret

RNB Retail and Brands AB (publ) today announces that the Board of Directors of the Company has applied for company reorganization (Sw. företagsrekonstruktion) for the subsidiaries Departments & Stores Europe AB ("Departments & Stores"), Polarn O. Pyret AB ("Polarn O. Pyret") and Brothers AB ( "Brothers") (together "the Companies") at the Stockholm District Court. During the reorganization, the Companies will keep stores and e-commerce open. The decision to apply for reorganization is based on the liquidity crisis that the Companies are experiencing as a direct consequence of the global

Accelerated road to market approval for CERAMENT® G in the US – BONESUPPORT[TM] submits De Novo application

Lund, Sweden, 8 am CET, 23 March 2020 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company will submit a De Novo application to the US Food and Drug Administration (FDA) to obtain a market approval for the company's antibiotic-releasing product CERAMENT G. The application is specified for the indication osteomyelitis (bone infection) and can potentially result in an approval at the latter end of 2020.During the winter, BONESUPPORT has been in dialogue with the US Food and Drug Administration, the FDA, to investigate

Castellum begins construction on E.ON’s Nordic headquarters – invests 1.3 billion Swedish kronor in Malmö

Castellum is moving ahead with plans to start construction of a new office building, with E.ON as the major tenant, with an investment of approximately SEK 1.3 billion, including land acquisitions. The building permit has now been issued and construction will begin Q2, 2020.Castellum is building a new Nordic head office for E.ON, to serve as the workplace of approx. 1,500 employees in the Nyhamnen district, located near Malmö’s Central Station. Skanska is the procured entrepreneur for the project. “In these times of concern caused by the Covid-19 virus, it feels gratifying to continue

Collector’s rights issue fully subscribed

The information in this press release is not intended for publication, public release or distribution, directly or indirectly, in or into the United States, Australia, Hong Kong, Canada, Singapore or any other jurisdiction where such publication or distribution would violate applicable laws or regulations. See the section “Important information” at the end of this press release.A preliminary count of the result in Collector AB’s rights issue shows that approximately 101.3 million shares have been subscribed for by the exercise of subscription rights, which is equivalent to approximately 98.

EUROBATTERY MINERALS ANNOUNCES RESEARCH RESULTS ON VANADIUM RECOVERY IN ITS PROSPECT AREA IN FETSJÖN, VÄSTERBOTTEN

· First results from Eurobattery Mineral’s collaboration with Uppsala University and the AGH University of Science & Technology in Krakow   · According to field studies and microprobe analyses conducted by the scientists from the universities, a certain type of the mineral Rutile is the carrier of vanadium in Eurobattery Mineral’s prospect area in Fetsjön   · Next step in research project is to initiate test to obtain the vanadium in a sustainable way   Eurobattery Minerals AB (NGM; “BAT"), a growth company in the mineral exploration industry with a corporate vision to

Skanska builds new office building for Castellum in Malmö, Sweden, for about SEK 920 M

Skanska has signed a contract with the real estate company Castellum to build E.ON's new Nordic headquarters in Nyhamnen, Malmö, Sweden. The contract is worth about SEK 920 M, which will be included in the order bookings for Sweden for the first quarter 2020.The project covers 36,000 square meters of gross area and the building will be between 8 and 9 floors high with a restaurant, gym and roof terrace, with the opportunity to work outdoors during the summer. The office building meets high sustainability requirements and will be certified according to Breeam. In addition, great focus is

All patients in the European MOB-015 Phase 3 study have completed their last visit

STOCKHOLM, March 23[rd], 2020 - Moberg Pharma AB (publ) announces that all patients in the European MOB-015 Phase 3 study have completed their last study visit. The data collection in the study were completed without any negative impact from COVID-19. The timeline remains unchanged with topline results expected by the end of the second quarter.MOB-015 is a new topical treatment of onychomycosis based on Moberg’s patented proprietary formulation of terbinafine. In the European study, 452 patients were initially randomized and 379 patients completed the study resulting in a drop-out rate of

There are no items matching the current filter
There are no more items matching the current filter
Back to top